Test of the Month

You have full text access to this OnlineOpen article

Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines†

  1. William L. Nichols1,2,*,
  2. Margaret E. Rick3,
  3. Thomas L. Ortel4,5,
  4. Robert R. Montgomery6,7,
  5. J. Evan Sadler8,
  6. Barbara P. Yawn9,10,
  7. Andra H. James11,
  8. Mae B. Hultin12,
  9. Marilyn J. Manco-Johnson13,14,
  10. Mark Weinstein15

Article first published online: 16 MAR 2009

DOI: 10.1002/ajh.21405

Issue

American Journal of Hematology

American Journal of Hematology

Volume 84, Issue 6, pages 366–370, June 2009

Additional Information

How to Cite

Nichols, W. L., Rick, M. E., Ortel, T. L., Montgomery, R. R., Sadler, J. E., Yawn, B. P., James, A. H., Hultin, M. B., Manco-Johnson, M. J. and Weinstein, M. (2009), Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines. Am. J. Hematol., 84: 366–370. doi: 10.1002/ajh.21405

Author Information

  1. 1

    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota

  2. 2

    Coagulation Clinic and Comprehensive Hemophilia Center, Division of Hematology and Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota

  3. 3

    Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland

  4. 4

    Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina

  5. 5

    Clinical Coagulation Laboratory, Department of Pathology, Duke University Medical Center, Durham, North Carolina

  6. 6

    Blood Research Institute, Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin

  7. 7

    Section of Pediatric Hematology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

  8. 8

    Department of Medicine, Washington University, St. Louis, Missouri

  9. 9

    Department of Research, Olmsted Medical Center, Rochester, Minnesota

  10. 10

    Department of Family and Community Medicine, University of Minnesota, Minneapolis, Minnesota

  11. 11

    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina

  12. 12

    Department of Medicine, Stony Brook University, Stony Brook, New York

  13. 13

    Department of Pediatrics, University of Colorado Denver, Aurora, Colorado

  14. 14

    Center for Cancer and Blood Disorders, Children's Hospital of Denver, Denver, Colorado

  15. 15

    Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland

*Special Coagulation Laboratory and Comprehensive Hemophilia Center, Hilton 200, Mayo Clinic, 200 First St SW, Rochester, MN 55905

  1. †

    Authors disclosing potential conflicts of interest are Dr. Andra James (speaking and consulting fees, and research support from CSL Behring, and honoraria from Grifols), Dr. Marilyn Manco-Johnson (speaking and consulting fees, and research support from CSL Behring), Dr. Robert Montgomery (consultant for Baxter, CSL Behring, GTI-Diagnostics, and Astra Zeneca; CSL Behring fellowship for research support), Dr. William Nichols (CSL Behring Humate-P surgical trial study, supervision of “central laboratory” activities at the Mayo Special Coagulation Laboratory, via contract through Mayo Clinical Trials Services), Dr. Thomas Ortel (speaking fee from CSL Behring), and Dr. J. Evan Sadler (consultant and Clinical Advisory Board member for Baxter). Drs. Margaret Rick and Mark Weinstein reported no potential conflicts of interest and contributed to this manuscript in their private capacities, and no official endorsement or support by the National Institutes of Health or the Food and Drug Administration is intended or should be inferred. All other authors reported no potential conflicts of interest.

Publication History

  1. Issue published online: 26 MAY 2009
  2. Article first published online: 16 MAR 2009
  3. Accepted manuscript online: 16 MAR 2009 12:00AM EST
  4. Manuscript Accepted: 9 MAR 2009
  5. Manuscript Revised: 4 MAR 2009
  6. Manuscript Received: 6 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (310K)

Abstract

Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects males and females, and reflects deficiency or defects of VWF that may also cause decreased FVIII. It may also occur less commonly as an acquired disorder (acquired von Willebrand syndrome). This article briefly summarizes selected features of the March 2008 evidence-based clinical and laboratory diagnostic recommendations from the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel for assessment for VWD or other bleeding disorders or risks. Management of VWD is also addressed in the NHLBI guidelines, but is not summarized here. The VWD guidelines are available at the NHLBI Web site (http://www.nhlbi.nih.gov/guidelines/vwd). Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.

Get PDF (310K)